Some startups run quiet in the lab, chasing whispers of innovation. Others, like Dilon Technologies, bring the noise and clarity of a gamma probe straight to the heart of a $250M market.
This isn’t just another medtech raise. This is a calculated move from a company that doesn’t need hype because the clinical data already does the talking. On June 9, 2025, Dilon Technologies locked in $9 million in growth capital from JGB Management Inc., a firm that doesn’t place bets, it places convictions. Founded by Brett Cohen, JGB knows niche credit like Dilon knows surgical precision.
Let’s talk strategy. The play here isn’t bloated R&D budgets or buzzword bingo. This round fuels U.S. sales force growth and tightens international grip, 76 countries and counting. If you’re wondering how a Newport News operation went global, look no further than execution. Since joining Virginia’s VALET program in 2020, Dilon’s international sales have surged 300%. That’s not expansion. That’s velocity.
And velocity needs leadership. Enter George Makhoul, CEO since July 2022, who didn’t show up to manage. He came to build. From Stryker to Biom’Up, his résumé reads like a surgical masterclass. Makhoul brought in HEMOBLAST® and reshaped Dilon into a biosurgery contender overnight. Now with Tim Jette as CFO, fresh off a $6B run at Medtronic and a high-growth streak at NanoHive Medical, the finance engine’s as sharp as the tech.
But Dilon doesn’t just collect smart people and cash checks. It builds. MarginProbe® cut re-excisions by 42% in DCIS cases, with a next-gen model at the FDA’s doorstep. HEMOBLAST®? The only FDA-approved powdered hemostat for moderate bleeding. No gimmicks, just a thrombin-collagen-chondroitin matrix that’s already saving OR time in 400+ U.S. hospitals. Navigator™ 2.0 is en route, doubling down on radio-guided surgical accuracy while keeping contamination at bay with sterilizable stainless steel. Even their complementary tech, the TrueView® 100 Pro and CoPilot VL+®, makes it clear: this isn’t a one-hit wonder. This is a surgical ecosystem in motion.
And let’s not gloss over the business lessons here. First, timing matters. Dilon raised $21.1M in the last 18 months, not from hope, but from proof. Second, differentiation is defense. With dual PMA Class III devices and a direct-to-hospital model, they’ve built a moat that’s part tech, part trust. Third? The best marketing is performance. No need for slogans when surgeons are already onboard.
So here’s to Dilon Technologies, a company that doesn’t shout, it demonstrates. From breast margins to bleeding control, they’ve turned precision into a product line and global traction into a strategy. With $9 million more in the war chest, profitability on the radar, and a product roadmap sharper than a surgical scalpel, they’re not just scaling, they’re operating.
